Azura heads for final studies for world-first dry eye treatment

Original article by Yolanda Redrup
The Australian Financial Review – Page: 21 : 8-Mar-21

Biotech start-up Azura Opthalmics is seeking to develop a treatment for a type of dry eye ailment known as meibomian gland dysfunction, which impacts over 30 million people in the US alone. Meibomian gland dysfunction can occur naturally as people age, but it can also be triggered or made worse by co-morbidities such as rheumatoid arthritis. Azura Opthalmics released promising phase two clinical trial results for its treatment in the week ending 5 March, while its backers include Brandon Capital, OrbiMed and Ganot Capital.

CORPORATES
AZURA OPTHALMICS, BRANDON CAPITAL PARTNERS PTY LTD, ORBIMED ADVISORS LLC, GANOT CAPITAL

CSL signs deal to make two Covid vaccines

Original article by Jared Lynch
The Australian – Page: 15 : 8-Sep-20

Biopharmaceutical giant CSL has secured a $1.7bn deal with the federal government to produce 80 million doses of two coronavirus vaccine candidates. This comprises 30 million doses of the vaccine that is being developed by Oxford University and AstraZeneca, and 50 million doses of the vaccine that CSL is developing with the University of Queensland. Phase three clinical trials have commenced on the Oxford vaccine, while the home-grown vaccine is in phase one trials. The government will contribute $300m to the cost of upgrading CSL’s advanced manufacturing facility in Melbourne to produce the vaccines.

CORPORATES
CSL LIMITED – ASX CSL, OXFORD UNIVERSITY, ASTRAZENECA PLC

CSL to step up flu vaccine production

Original article by Jared Lynch
The Australian – Page: 15 : 20-Apr-20

CSL subsidiary Seqirus will produce an additional two million doses of the influenza vaccine, amid strong demand during the coronavirus pandemic. Danielle Dowell of Seqirus says the company is set to supply a record number of flu shots during the 2020 flu season, and stresses that consumers should call their pharmacy or medical clinic ahead of time to ensure that the vaccine is available. The federal government will provide 13.5 million free flu shots via its National Immunisation Program. The flu vaccine does not provide protection against the coronavirus.

CORPORATES
CSL LIMITED – ASX CSL, SEQIRUS PTY LTD, SIGMA HEALTHCARE LIMITED – ASX SIG, AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED – ASX API

CSL launches $1b share buyback

Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 16-Oct-15

Australian-listed CSL forecasts that its Seqirus influenza division will post revenue of $US450m and a break-even profit in 2015-16, before making a profit in 2017-18. Seqirus has been established by merging the BioCSL division with the recently acquired flu vaccines arm of Novartis. Meanwhile, CSL will repurchase some $A1bn of its shares over the next year. It will be the group’s ninth buyback in the last decade.

CORPORATES
CSL LIMITED – ASX CSL, BIOCSL, SEQIRUS, NOVARTIS AG, UBS HOLDINGS PTY LTD

Deal lifts Starpharma shares 21pc

Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 8-Sep-15

Shares in Australian biotechnology group Starpharma closed 21.3 per cent higher at $A0.74 on 7 September, after securing a licensing agreement with AstraZeneca for the use of its dendrimer drug delivery technology. Starpharma CEO Jackie Fairley say the deal could potentially be worth at least $US450m to the company. Starpharma recently posted a 2014-15 loss of $A18.95m.

CORPORATES
STARPHARMA HOLDINGS LIMITED – ASX SPL, ASTRAZENECA PLC, McGRATH REAL ESTATE PTY LTD, ALLAN GRAY AUSTRALIA PTY LTD, FIDELITY INVESTMENTS AUSTRALIA LIMITED

Skin cancer drug developer plans to list

Original article by Sally Rose
The Australian Financial Review – Page: 19 : 29-Sep-14

Melbourne-based Ascend Biopharmaceuticals will offer its shares at $A0.35 in an IPO that aims to raise between $A9m and $A11m. Proceeds of the float will be used to finance clinical trials of drugs that are intended to treat skin cancer and breast cancer. Ascend shares are slated to list on the Australian sharemarket on 14 November 2014

CORPORATES
ASCEND BIOPHARMACEUTICALS LIMITED, ONYVAX, ALCHEMIA LIMITED – ASX ACL, AMRAD CORP LIMITED, F HOFFMAN-LA ROCHE LIMITED, F HOFFMAN-LA ROCHE AG, IMMATICS, LODGE CORPORATE PTY LTD, TRANSGENE

Mesoblast sows the seeds for stem cell success

Original article by Rick Wallace
The Australian – Page: 15 & 16 : 28-Jul-14

A new regulatory environment in Japan means it will be the initial market in which Australian-listed biotechnology group Mesoblast launches its revolutionary stem cells therapy product. CEO Silviu Itescu notes that this will be a world first, and should boost stock analysts’ forecasts for the company. A 2016 launch in the US is also being aimed for. In that nation Mesoblast has concluded phase III clinical trials of mesenchymal stem cells for treating childhood graft-versus-host-disease. The group has cash holdings of about $A220m, and can allocate funding to separate trials of its degenerative disc repair product

CORPORATES
MESOBLAST LIMITED – ASX MSB, UNITED STATES. FOOD AND DRUG ADMINISTRATION, JCR PHARMACEUTICALS COMPANY LIMITED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, GOLDMAN SACHS AUSTRALIA PTY LTD, BELL POTTER SECURITIES LIMITED, BELL FINANCIAL GROUP LIMITED – ASX BFG